ESGE

FUJIFILM Europe launches new virtual scale solution to address challenges faced by endoscopists in polyp measurement

Retrieved on: 
Friday, April 21, 2023
ESGE, EYE, Fujifilm, CAD, Cancer, Innovation system, Research, Large intestine, Associate, Colon, Colorectal cancer, SCALE, Patient, Physician, Hearing, Colonoscopy, Diagnosis, Polyp, Medical imaging, Gastroenterology, Humanitas University

To support endoscopists, FUJIFILM Europe has launched SCALE EYE, a virtual scale solution designed to support endoscopists in estimating the size of lesions in the colon.

Key Points: 
  • To support endoscopists, FUJIFILM Europe has launched SCALE EYE, a virtual scale solution designed to support endoscopists in estimating the size of lesions in the colon.
  • Integrated into FUJIFILM's ELUXEO Ultra platform, SCALE EYE enables endoscopists to measure polyps more accurately and as a result, support physicians to determine the treatment needed by simply pressing a switch.
  • Despite 90 percent of the endoscopists agreeing on the importance of polyp measurement, the majority use visual estimation, open biopsy forceps, or endoscopic rulers, rather than innovative solutions.
  • [2]
    Prof Cesare Hassan, Associate Professor of Gastroenterology, Humanitas University, Italy said: "SCALE EYE is a disruptive technology by Fujifilm.

FUJIFILM Europe launches new virtual scale solution to address challenges faced by endoscopists in polyp measurement

Retrieved on: 
Friday, April 21, 2023
ESGE, EYE, Fujifilm, CAD, Cancer, Innovation system, Research, Large intestine, Associate, Colon, Colorectal cancer, SCALE, Patient, Physician, Hearing, Colonoscopy, Diagnosis, Polyp, Medical imaging, Gastroenterology, Humanitas University

To support endoscopists, FUJIFILM Europe has launched SCALE EYE, a virtual scale solution designed to support endoscopists in estimating the size of lesions in the colon.

Key Points: 
  • To support endoscopists, FUJIFILM Europe has launched SCALE EYE, a virtual scale solution designed to support endoscopists in estimating the size of lesions in the colon.
  • Integrated into FUJIFILM's ELUXEO Ultra platform, SCALE EYE enables endoscopists to measure polyps more accurately and as a result, support physicians to determine the treatment needed by simply pressing a switch.
  • Despite 90 percent of the endoscopists agreeing on the importance of polyp measurement, the majority use visual estimation, open biopsy forceps, or endoscopic rulers, rather than innovative solutions.
  • [2]
    Prof Cesare Hassan, Associate Professor of Gastroenterology, Humanitas University, Italy said: "SCALE EYE is a disruptive technology by Fujifilm.

LUMENDI KEY OPINION LEADER, DR. ROBERTA MASELLI, RECEIVES INNOVATION OF THE YEAR AWARD FOR THE BEST NEW DEVICE FROM THE EUROPEAN SOCIETY OF GASTROINTESTINAL ENDOSCOPY (ESGE)

Retrieved on: 
Thursday, April 20, 2023
Society, ESGE, Extrapyramidal system, Gastrointestinal Endoscopy, Endoscopy, Assistant, Congress, Rectum, Balloon, ESD, European Society of Neurogastroenterology and Motility, Humanitas University, Safety, Award, Medical device

MAIDENHEAD, United Kingdom, April 20, 2023 /PRNewswire/ -- UK-based medical device innovator Lumendi Ltd., today announced that the European Society of Gastrointestinal Endoscopy (ESGE) has awarded company consultant and key opinion leader, Dr. Roberta Maselli, Assistant Professor of Gastroenterology at Humanitas University in Milan, Italy, the 'Best New Device" award for the Balloon Endo-Luminal Lumen Occluding (BELLO) Device. The prestigious award was presented to Dr. Maselli earlier today, at the Society's ESGE Days 2023 congress, currently being held in Dublin, Ireland through April 22, 2023, and virtually.

Key Points: 
  • The prestigious award was presented to Dr. Maselli earlier today, at the Society's ESGE Days 2023 congress, currently being held in Dublin, Ireland through April 22, 2023, and virtually.
  • The BELLO is a new, modified device designed to facilitate technically demanding endoscopic submucosal dissection procedures of the lower gastrointestinal tract, especially of rectal lesions.
  • "The BELLO is an important innovation and upon approval, would allow safer, more efficient submucosal dissection procedures in the rectum.
  • With its numerous potential benefits, including improved safety, accuracy, and patient comfort, it has the ability to revolutionize the way early gastrointestinal neoplasia are treated," stated Dr. Maselli.

TissueCypher® Test Results Can Increase the Likelihood of Appropriate Management Decisions for Barrett’s Esophagus Patients with Low-Grade Dysplasia

Retrieved on: 
Thursday, April 20, 2023
Research, Clinical Trials, Biotechnology, Other Health, Health, Pharmaceutical, Other Science, Science, Oncology, ESGE, LGD, Pathology, Gastrointestinal Endoscopy, BE, Dysplasia, Patient, Risk, Esophageal cancer, Diagnosis, EET, European Society of Gynaecological Oncology, Medical device, Medical imaging

Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced new data from a patient simulation study which showed that, compared to pathology alone, TissueCypher® Barrett’s Esophagus test results may significantly increase the likelihood of appropriate management decisions for Barrett’s esophagus (BE) patients with low-grade dysplasia (LGD) according to their risk of progressing to esophageal cancer.

Key Points: 
  • Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced new data from a patient simulation study which showed that, compared to pathology alone, TissueCypher® Barrett’s Esophagus test results may significantly increase the likelihood of appropriate management decisions for Barrett’s esophagus (BE) patients with low-grade dysplasia (LGD) according to their risk of progressing to esophageal cancer.
  • Overall, the study results showed that TissueCypher standardized the management of BE cases with LGD to improve health outcomes by potentially:
    Reducing unnecessary use of EET and endoscopies for low-risk patients.
  • Overall, the study data showed that, compared to pathology alone, using TissueCypher test results to guide management decisions significantly increased the likelihood that BE patients with LGD could receive appropriate management per their known outcome (p=0.0002), which supports use of the test to help standardize the management of BE patients to potentially improve their overall care and health outcomes.
  • The presentation will be given by lead study author Amir Khoshiwal, M.D., from the research team of Dr. Bergman.

AbbVie Highlights Robust Gastroenterology Portfolio with New Analyses and Data in Inflammatory Bowel Diseases at the 18th Congress of European Crohn's and Colitis Organisation (ECCO)

Retrieved on: 
Monday, February 27, 2023
Gastrointestinal Endoscopy, Boehringer Ingelheim, Congress, Medicine, University, Endoscopy, CD, European Society of Neurogastroenterology and Motility, Inflammatory Bowel Diseases, NYSE, Disease, UC, Research, Pharming, Gastroenterology, Standard of care, Patient, Abstract, Inflammatory bowel disease, ESGE, Ulcerative colitis, ECCO, Pain, AbbVie, Debate, Fatigue, Crohn's disease, IBD, NORTH, Risankizumab, Pharmaceutical industry, Financial adviser

AbbVie will present 24 abstracts, including four oral presentations, two digital oral presentations and 18 posters from a broad range of studies across its inflammatory bowel disease (IBD) portfolio.

Key Points: 
  • AbbVie will present 24 abstracts, including four oral presentations, two digital oral presentations and 18 posters from a broad range of studies across its inflammatory bowel disease (IBD) portfolio.
  • "We are excited by the opportunity to present further analyses on the advancements of our expanding IBD portfolio at this year's 18th ECCO Congress," said Sofie Berg, Pharm.D, Ph.D., head of gastroenterology, global medical affairs, AbbVie.
  • Ph.D. director of gastroenterology and endoscopy at IRCCS Ospedale San Raffaele and professor of gastroenterology at University Vita-Salute San Raffaele, Milan, Italy.
  • SKYRIZI® (risankizumab) is part of a collaboration between Boehringer Ingelheim and AbbVie, with AbbVie leading development and commercialization globally.

FUJIFILM Europe launches new software for SCALE EYE¹, a real-time virtual scale function to aid endoscopists in estimating the size of lesions in the colon

Retrieved on: 
Thursday, October 6, 2022
Physician, Colon, Endoscopy, Diagnosis, Vaccine, CAD, Patient, Gastrointestinal Endoscopy, Polyp (medicine), Research, Colonoscopy, Support, Colorectal cancer, Technology, Cancer, Deep learning, ESGE, Software, World Cancer Day, Percussion section, Endoscopic mucosal resection, AI, Incidence, Health, EYE, ESD, Photography, Artificial intelligence, GLOBE, SCALE, EMR, Regenerative medicine, Large intestine, Solution, European Commission, Medical imaging, Telescopic sight, Medical device, Fujifilm

RATINGEN, Germany, Oct. 06, 2022 (GLOBE NEWSWIRE) -- FUJIFILM Europe GmbH has launched the new software EW10-VM01 for SCALE EYE real-time virtual scale function (“SCALE EYE”), designed to help endoscopists estimate the size of lesions in the colon. SCALE EYE is the latest technology to be launched as part of the ELUXEO Ultra platform, delivering a comprehensive package for endoscopists.

Key Points: 
  • RATINGEN, Germany, Oct. 06, 2022 (GLOBE NEWSWIRE) -- FUJIFILM Europe GmbH has launched the new software EW10-VM01 for SCALE EYE real-time virtual scale function (SCALE EYE), designed to help endoscopists estimate the size of lesions in the colon.
  • Fujifilm has developed SCALE EYE, a function designed to aid endoscopists in estimating the size of lesions in the colon.
  • The SCALE EYE system includes the newly developed endoscope EC-760S-A/M, L, which is equipped with a class 1 laser.
  • 1 SCALE EYE is a Fujifilm brand name of function to support size estimation by virtual scale.

Italian pharmaceutical company Alfasigma launches diagnostic drug Lumeblue™ ahead of World Digestive Health on 29 May

Retrieved on: 
Friday, May 27, 2022
Department, ESGE, Physician, Colon, Risk, Endoscopy unit, Death, Disease, HD, CRC, Incidence, Health, University of Kansas School of Medicine, European Medicines Agency, ADR, Patient, Colonoscopy, Internal medicine, Mortality, Section, Artificial intelligence, Institute, Gastroenterology, Methylene blue, Awareness, EMA, III, University, Pamlab, Colorectal cancer, Adoption, Chromoendoscopy, Pharmaceutical industry, European Economic Area, EU

BOLOGNA, Italy, May 27, 2022 /PRNewswire/ -- Ahead of World Digestive Health 2022, Italian pharmaceutical group Alfasigma is proud to announce the launch of its new diagnostic drug Lumeblue™ (per-oral methylene blue). This latest innovation is part of the company's commitment to raising awareness on colorectal cancer (CRC), still the second leading cause of cancer deaths worldwide, through a healthy lifestyle and regular screenings.

Key Points: 
  • BOLOGNA, Italy, May 27, 2022 /PRNewswire/ -- Ahead of World Digestive Health 2022, Italian pharmaceutical group Alfasigma is proud to announce the launch of its new diagnostic drug Lumeblue (per-oral methylene blue).
  • Lumeblue is approved by EMA (European Medicines Agency) for the detection of lesions during colonoscopy.
  • Lumeblue was in a symposium titled "A new tool in colonoscopy: Per-oral methylene blue" at ESGE Days 2022 as a new diagnostic drug to improve the detection of lesions during colonoscopy.
  • Privately owned, Alfasigma is an Italy-based multinational pharmaceutical company with a presence in over 90 countries through distributors and subsidiaries.

Fujifilm launches mobile training hub to tackle endoscopy challenges as clinicians warn cancers will be more difficult to treat post-COVID

Retrieved on: 
Wednesday, April 27, 2022
Solution, CAD, Artificial intelligence, Deep learning, Cancer, Percussion section, Patient, ESGE, Education, Endoscopy, Learning, Gastrointestinal Endoscopy, COVID-19, Quality of life, United Kingdom, EYE, Photography, Diagnosis, Hospital, AI, Senior, Marketing, Research, Physician, Particle-size distribution, GI, European Society for Primary Immunodeficiencies, Health, Tourism, Pharmaceutical industry, Medicine, Healthcare, Fujifilm

PRAGUE, April 28, 2022 /PRNewswire/ -- Fujifilm has today launched a first of its kind mobile training hub at ESGE Days to help tackle some of the biggest challenges in endoscopy, as new research shows concern among endoscopists about the impact of the pandemic on cancer services.

Key Points: 
  • The survey of endoscopists and gastroenterology professionals from across Europe was undertaken by Sermo on behalf of Fujifilm.
  • COVID-19 has had a significant impact on learning, with over two thirds (67%) saying it had reduced opportunities for training and education.
  • Having heard the challenges faced by endoscopists, Fujifilm has developed the EndoRunner, a mobile hub with their complete endoscopic solutions portfolio which travels to clinicians to support their training.
  • Congratulations to Fujifilm for a fantastic innovation that will support clinicians as endoscopy services are recovered following the pandemic.

PENTAX Medical Appoints Dr. Klaus Mergener, MD, PhD, MBA as Chief Medical Officer

Retrieved on: 
Friday, April 8, 2022
American Society for Gastrointestinal Endoscopy, Endoscopy, German Cancer Aid, Duke University, Therapy, State, University of Washington School of Medicine, Partnership, Gastroenterology, WEO, Multimedia, Doctor of Philosophy, ASGE, Internal medicine, Harvard University, View, MD, Health, American College of Gastroenterology, Nobel Prize, Industry, University of Massachusetts Medical School, Goal, Society, American College, ESGE, MBA, European Society for Medical Oncology, Solution, Gastrointestinal Endoscopy, Efficiency, German Cancer Research Center, Education, University, Patient, ACG, Affiliation, Management, Medical device, Medicine, Medicine

TOKYO, April 8, 2022 /PRNewswire/ -- PENTAX Medical, a division of HOYA Group, has announced the appointment of Dr. Klaus Mergener, MD, PhD, MBA to the position of Chief Medical Officer of PENTAX Lifecare Division (PENTAX Medical) as of April 1st, 2022.

Key Points: 
  • TOKYO, April 8, 2022 /PRNewswire/ -- PENTAX Medical, a division of HOYA Group, has announced the appointment of Dr. Klaus Mergener, MD, PhD, MBA to the position of Chief Medical Officer of PENTAX Lifecare Division (PENTAX Medical) as of April 1st, 2022.
  • "We are pleased to have Dr. Klaus Mergener support PENTAX Medical in driving our mission to become the preferred choice in flexible endoscopy from screening to therapeutics providing for integrated solutions to optimize patient care," said Rainer Burkard, Global President of PENTAX Medical.
  • I am very much looking forward to assisting the global PENTAX Medical team in this effort."
  • Rainer Burkard commented: "Working closely with professional medical organizations and key opinion leaders around the world is critically important for PENTAX Medical to identify medical trends, and to partner in clinical studies and education.

PENTAX Medical Appoints Dr. Klaus Mergener, MD, PhD, MBA as Chief Medical Officer

Retrieved on: 
Friday, April 8, 2022
American Society for Gastrointestinal Endoscopy, Endoscopy, German Cancer Aid, Duke University, Therapy, State, University of Washington School of Medicine, Partnership, Gastroenterology, WEO, Doctor of Philosophy, ASGE, Internal medicine, Harvard University, MD, Health, American College of Gastroenterology, Nobel Prize, Industry, University of Massachusetts Medical School, Goal, Society, American College, ESGE, MBA, European Society for Medical Oncology, Solution, Gastrointestinal Endoscopy, Efficiency, German Cancer Research Center, Education, University, Patient, ACG, Affiliation, Medical device, Medicine, Medicine

TOKYO, April 8, 2022 /PRNewswire/ -- PENTAX Medical, a division of HOYA Group, has announced the appointment of Dr. Klaus Mergener, MD, PhD, MBA to the position of Chief Medical Officer of PENTAX Lifecare Division (PENTAX Medical) as of April 1st, 2022.

Key Points: 
  • TOKYO, April 8, 2022 /PRNewswire/ -- PENTAX Medical, a division of HOYA Group, has announced the appointment of Dr. Klaus Mergener, MD, PhD, MBA to the position of Chief Medical Officer of PENTAX Lifecare Division (PENTAX Medical) as of April 1st, 2022.
  • "We are pleased to have Dr. Klaus Mergener support PENTAX Medical in driving our mission to become the preferred choice in flexible endoscopy from screening to therapeutics providing for integrated solutions to optimize patient care," said Rainer Burkard, Global President of PENTAX Medical.
  • I am very much looking forward to assisting the global PENTAX Medical team in this effort."
  • Rainer Burkard commented: "Working closely with professional medical organizations and key opinion leaders around the world is critically important for PENTAX Medical to identify medical trends, and to partner in clinical studies and education.